Close menu




DEFENCE THERAPEUTICS INC

Photo credits: pixabay.com

Commented by Stefan Feulner on October 21st, 2021 | 12:17 CEST

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

Read

Commented by Carsten Mainitz on October 12th, 2021 | 12:32 CEST

Defence Therapeutics, BioNTech, Valneva - When will things pick up again?

  • Biotechnology

Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?

Read

Commented by André Will-Laudien on October 8th, 2021 | 10:25 CEST

BioNTech, Defence Therapeutics, Valneva, Formycon - Close to the bio-revolution!

  • Biotechnology

Portugal is one of the countries with the highest vaccination rate, with 86% of the population already vaccinated. Approximately 98% of those eligible for vaccination - including everyone over the age of 12 - have been vaccinated. Germany, with about 64%, is one of the more vaccine-weary nations. What is the secret of the Portuguese? The government relied on an opinion maker from within its ranks, Admiral Gouveia e Melo. An expert in complicated logistical tasks in the military, he was appointed in February as the top leader of the national vaccination campaign. He is never seen without his military combat uniform in numerous public television appearances - and when asked how other countries can move their own vaccination effort forward, the admiral did not hesitate to offer his best advice: "You have to find people who are not politicians." Where are the current opportunities in the vaccination sector?

Read

Commented by Armin Schulz on September 27th, 2021 | 13:24 CEST

Valneva, Defence Therapeutics, CureVac - Second-tier vaccine makers offer high potential

  • Biotechnology

The battle against the Coronavirus is still ongoing, although more and more people have been vaccinated with vector or mRNA vaccines. In Europe, an average of 60% of all people have received the vaccination. Herd immunity has not yet been achieved, in part because of vaccine skeptics who do not yet trust novel vaccines. New vaccines based on dead viruses promise to remedy the situation. This method has already been tried and tested in influenza vaccinations, for example. According to a study in Switzerland, about 70% of the unvaccinated would still be vaccinated if the method had already been tested. Herd immunity could thus be achieved, and everyday life could return to normal. So, which vaccine manufacturer that does not currently have an approved product could shake up the market?

Read

Commented by Fabian Lorenz on September 24th, 2021 | 14:10 CEST

BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?

  • Biotechnology

Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.

Read

Commented by Nico Popp on September 14th, 2021 | 13:10 CEST

BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter

  • Biotechnology

Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.

Read

Commented by Stefan Feulner on September 3rd, 2021 | 13:27 CEST

MorphoSys, Defence Therapeutics, CureVac, BioNTech - Dramatic need

  • Biotechnology

While in Germany, 50.4 million citizens, or 60.7% of the population, are already fully vaccinated, and there is already discussion about booster vaccinations, the global average is just one in four. Thus, there is still an enormous demand for vaccines from various manufacturers. In addition to the French pharmaceutical Company Sanofi, a German vaccine producer could also celebrate a stock market comeback due to its second-generation vaccine.

Read

Commented by André Will-Laudien on August 23rd, 2021 | 12:25 CEST

BioNTech, Defence Therapeutics, Dermapharm, NanoRepro - Vaccinate, Test, Treat!

  • Biotechnology

The vaccination rate in Germany is now just under 59% with complete second vaccination. The Ministry of Health had assumed a 70-80% rate by late summer. The situation has now changed, and the autumn in Germany will likely take place under different conditions. Since the beginning of August, the many travelers returning home have had to undergo a test at the entry border to Germany. Presumably, the number of infections will also rise again, making testing mandatory for social life. Vaccination and testing, therefore, remain ongoing issues for the capital markets.

Read

Commented by Carsten Mainitz on August 16th, 2021 | 11:20 CEST

Defence Therapeutics, Moderna, Evotec - Bet on the front-runners!

  • Biotechnology

Health is our most important asset. Biotech companies that protect it save not only human lives but also reap high profits. The price development of many biotech stocks over the past few months has been breathtaking. Investors are advised to focus on the frontrunners, as the market position gained as a first mover, the leadership position in a niche or innovative solution, will enable the companies to keep their competitors at bay for a long time to come.

Read

Commented by André Will-Laudien on August 4th, 2021 | 11:23 CEST

MorphoSys, Defence Therapeutics, BioNTech, Pfizer - The next biotech explosion!

  • Biotechnology

Infectious diseases are diseases transmitted by pathogens such as bacteria, viruses or fungi. Depending on which organs and body parts they affect, they can cause very different symptoms. In Covid-19, we are dealing with a problematic initial situation because not every infected person has apparent symptoms at all. Moreover, the virus can also be transmitted from vaccinated individuals to the next host without any problems. That shows the high relevance of testing, despite increasing vaccination rates. On the one hand, the biotech sector is concerned with diagnostic procedures and, on the other hand, with suitable vaccinations to best prepare our immune system for the fight. In the current pandemic, the coming winter will also indicate the overall effectiveness of vaccines.

Read